|
Cannevert Therapeutics Ltd., the research partner of Veritas Pharma Inc, an early stage pharmaceutical company, has obtained an exemption from Health Canada to legally perform cannabis research.
“We’re pleased with Health Canada’s approval. Cannevert scientists can now begin the hard work of screening the various cannabis cultivars from Whistler Medical Marijuana Corporation,” explained Veritas CEO, Lui Franciosi. Health Canada also granted permission for the scientists to use other controlled substances to better understand the effects of cannabis.
Cannevert welcomes this government decision since the regulatory approval and authorisation enables the researchers to obtain sufficient varieties of cannabis on a regular basis to ensure rapid scientific progress. The necessary chemical and pharmacological assays have been already calibrated and standardised so allowing full analysis of 2 to 3 cannabis strains on a weekly basis.
Veritas Pharma’s aim is to get the most appropriate cultivars into the clinic and obtain the necessary intellectual protection for those showing therapeutic potential for human diseases.
|